AIM: Large interindividual variability in morphine pharmacokinetics could contribute to variability in morphine analgesia and adverse events. METHODS: Influence of weight, genetic polymorphisms, race and sex on morphine clearance and metabolite formation from 220 children undergoing outpatient adenotonsillectomy was studied. A nonlinear mixed effects model was developed in NONMEM to describe morphine and morphine glucuronide pharmacokinetics. RESULTS: Children with ABCC3 -211C>T polymorphism C/C genotype had significantly higher levels of morphine-6-glucuronide and morphine-3-glucuronide formation (∼40%) than C/T+T/T genotypes (p < 0.05). In this extended cohort similar to our earlier report, OCT1 homozygous genotypes (n = 13, OCT1*2-*5/*2-*5) had lower morphine clearance (14%; p = 0.06), and in addition complementing lower metabolite formation (∼39%) was observed. ABCB1 3435C>T TT genotype children had lower levels of morphine-3-glucuronide formation though no effect was observed on morphine and morphine-6-glucuronide pharmacokinetics. CONCLUSION: Our data suggest that besides bodyweight, OCT1 and ABCC3 genotypes play a significant role in the pharmacokinetics of intravenous morphine and its metabolites in children.
AIM: Large interindividual variability in morphine pharmacokinetics could contribute to variability in morphineanalgesia and adverse events. METHODS: Influence of weight, genetic polymorphisms, race and sex on morphine clearance and metabolite formation from 220 children undergoing outpatient adenotonsillectomy was studied. A nonlinear mixed effects model was developed in NONMEM to describe morphine and morphine glucuronide pharmacokinetics. RESULTS:Children with ABCC3 -211C>T polymorphism C/C genotype had significantly higher levels of morphine-6-glucuronide and morphine-3-glucuronide formation (∼40%) than C/T+T/T genotypes (p < 0.05). In this extended cohort similar to our earlier report, OCT1 homozygous genotypes (n = 13, OCT1*2-*5/*2-*5) had lower morphine clearance (14%; p = 0.06), and in addition complementing lower metabolite formation (∼39%) was observed. ABCB1 3435C>T TT genotype children had lower levels of morphine-3-glucuronide formation though no effect was observed on morphine and morphine-6-glucuronide pharmacokinetics. CONCLUSION: Our data suggest that besides bodyweight, OCT1 and ABCC3 genotypes play a significant role in the pharmacokinetics of intravenous morphine and its metabolites in children.
Authors: Claudia F Clavijo; Keith L Hoffman; James J Thomas; Brendan Carvalho; Larry F Chu; David R Drover; Gregory B Hammer; Uwe Christians; Jeffrey L Galinkin Journal: Anal Bioanal Chem Date: 2011-03-12 Impact factor: 4.142
Authors: George L Scheffer; Marcel Kool; Marcel de Haas; J Marleen L de Vree; Adriana C L M Pijnenborg; Diederik K Bosman; Ronald P J Oude Elferink; Paul van der Valk; Piet Borst; Rik J Scheper Journal: Lab Invest Date: 2002-02 Impact factor: 5.662
Authors: Elyse M Cornett; Michelle A Carroll Turpin; Allison Pinner; Pankaj Thakur; Tamizh Selvan Gnana Sekaran; Harish Siddaiah; Jasmine Rivas; Anna Yates; G Jason Huang; Anitha Senthil; Narjeet Khurmi; Jenna L Miller; Cain W Stark; Richard D Urman; Alan David Kaye Journal: Curr Oncol Rep Date: 2020-02-06 Impact factor: 5.075
Authors: K L R Brouwer; L M Aleksunes; B Brandys; G P Giacoia; G Knipp; V Lukacova; B Meibohm; S K Nigam; M Rieder; S N de Wildt Journal: Clin Pharmacol Ther Date: 2015-09 Impact factor: 6.875
Authors: Massroor Pourcyrous; Mohamad T Elabiad; Divya Rana; Kan P Gaston; Linda DeBaer; Ramasubbareddy Dhanireddy Journal: Pediatr Res Date: 2020-11-19 Impact factor: 3.756
Authors: V Chidambaran; R Venkatasubramanian; X Zhang; L J Martin; J Niu; T Mizuno; T Fukuda; J Meller; A A Vinks; S Sadhasivam Journal: Pharmacogenomics J Date: 2016-01-26 Impact factor: 3.550